An update on the role of SMARCA4 deficiency in gynecological neoplasms: how and where.
2/5 보강
TL;DR
Current knowledge of the role of SMARCA4 deficiency in gynecological cancers is summarized, discussing the morphological and immunophenotypic characteristics of the different entities, emphasizing clinical implications and potential targeted therapies.
OpenAlex 토픽 ·
Chromatin Remodeling and Cancer
Protein Degradation and Inhibitors
Mechanisms of cancer metastasis
Current knowledge of the role of SMARCA4 deficiency in gynecological cancers is summarized, discussing the morphological and immunophenotypic characteristics of the different entities, emphasizing cli
APA
Livia Macciò, Emma Bragantini, et al. (2026). An update on the role of SMARCA4 deficiency in gynecological neoplasms: how and where.. Virchows Archiv : an international journal of pathology, 488(4), 721-733. https://doi.org/10.1007/s00428-025-04318-9
MLA
Livia Macciò, et al.. "An update on the role of SMARCA4 deficiency in gynecological neoplasms: how and where.." Virchows Archiv : an international journal of pathology, vol. 488, no. 4, 2026, pp. 721-733.
PMID
41449215 ↗
Abstract 한글 요약
SMARCA4, encoding the BRG1 protein, is a crucial component of the SWI/SNF chromatin remodeling complex, essential for regulating gene expression and maintaining genomic integrity; our knowledge regarding the role of these genes continues to evolve. Deficiency or loss of SMARCA4 expression has been implicated in the development and progression of various gynecological neoplasms, notably small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), SMARCA4-deficient uterine sarcoma, and some subtypes of endometrial carcinoma such as undifferentiated or dedifferentiated carcinoma. Given its central role in oncogenesis, targeting SMARCA4-deficient tumors has become an area of active research, with potential therapeutic strategies above all in these aggressive gynecological tumor subtypes. This review summarizes current knowledge of the role of SMARCA4 deficiency in gynecological cancers, discussing the morphological and immunophenotypic characteristics of the different entities, emphasizing clinical implications and potential targeted therapies. Further understanding of its structure, function, and therapeutic vulnerabilities is crucial for improving patient outcomes.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.